DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

PHASE3RecruitingINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

June 5, 2026

Study Completion Date

August 1, 2028

Conditions
HIV - Human Immunodeficiency VirusObesityOverweight and/or Obesity
Interventions
DRUG

DOR/3TC/TDF

It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100/300/300 mg

DRUG

BIC/FTC/TAF

It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.

Trial Locations (1)

02990

RECRUITING

Hospital de infectología, Centro Médico Nacional La Raza, Mexico City

All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

lead

José Antonio Mata Marín

OTHER_GOV